Orphazyme receives Wellcome Trust Pathfinder Award
The Wellcome Trust has awarded Orphazyme ApS the Pathfinder Award in collaboration with Professor Frances Platt's group at Oxford University. The grant is awarded for the project ‘Regulation of the Heat Shock Response as a Treatment for Niemann-Pick type C disease’, and is set to commence in October 2014. The Pathfinder Award is supporting academic/industry partnerships to develop applied R&D in orphan diseases. The award is given to projects with significant potential to help develop innovative products in the orphan and neglected disease area.
”This grant will support very important translational work, and bring us a step closer to providing much needed therapy to patients with Niemann-Pick type C disease. We are grateful for receiving this validation of the research performed by Professor Platt's group and Orphazyme," says Anders Hinsby, CEO of Orphazyme.
Anders Hinsby, CEO of Orphazyme
Orphazyme ApS is a Danish biopharmaceutical company, which develops paradigm-changing medicines for the treatment of genetic diseases. The lead program is in preclinical development as treatment for lysosomal storage diseases. This family of genetic disorders consists of more than 45 diseases, most of which are currently untreatable and often fatal. Orphazyme has raised more than 17 million euro in seed and series A financing, from a strong investor base which includes Novo Ventures, Sunstone Capital and Aescap Venture. For more information, please visit www.orphazyme.com.